122 related articles for article (PubMed ID: 1532459)
1. Pharmacologic rationale for fluoropyrimidine-leucovorin combination: biochemical mechanisms.
Zhang ZG; Rustum YM
Semin Oncol; 1992 Apr; 19(2 Suppl 4):46-50. PubMed ID: 1532459
[TBL] [Abstract][Full Text] [Related]
2. Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration.
Zhang ZG; Harstrick A; Rustum YM
Semin Oncol; 1992 Apr; 19(2 Suppl 3):10-5. PubMed ID: 1532669
[TBL] [Abstract][Full Text] [Related]
3. Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.
Houghton JA; Williams LG; Cheshire PJ; Wainer IW; Jadaud P; Houghton PJ
Cancer Res; 1990 Jul; 50(13):3940-6. PubMed ID: 2354443
[TBL] [Abstract][Full Text] [Related]
4. Effects of diastereoisomers of 5-formyltetrahydrofolate on cellular growth, sensitivity to 5-fluoro-2'-deoxyuridine, and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells.
Zhang ZG; Rustum YM
Cancer Res; 1991 Jul; 51(13):3476-81. PubMed ID: 2054787
[TBL] [Abstract][Full Text] [Related]
5. Enhanced inhibition of thymidylate synthase by 5-fluorouracil and [6S]leucovorin combination therapy for breast cancer.
Tominaga T; Toi M; Shirasaka T
Anticancer Res; 1993; 13(6B):2425-7. PubMed ID: 8135478
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin.
Mini E; Moroson BA; Bertino JR
Cancer Treat Rep; 1987 Apr; 71(4):381-9. PubMed ID: 2950995
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to fluoropyrimidines.
Zhang ZG; Harstrick A; Rustum YM
Semin Oncol; 1992 Apr; 19(2 Suppl 3):4-9. PubMed ID: 1532673
[TBL] [Abstract][Full Text] [Related]
8. Role for cytosolic folate-binding proteins in the compartmentation of endogenous tetrahydrofolates and the 5-formyl tetrahydrofolate-mediated enhancement of 5-fluoro-2'-deoxyuridine antitumor activity in vitro.
Matherly LH; Czajkowski CA; Muench SP; Psiakis JT
Cancer Res; 1990 Jun; 50(11):3262-9. PubMed ID: 2139802
[TBL] [Abstract][Full Text] [Related]
9. Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts.
Houghton JA; Williams LG; de Graaf SS; Cheshire PJ; Rodman JH; Maneval DC; Wainer IW; Jadaud P; Houghton PJ
Cancer Res; 1990 Jun; 50(12):3493-502. PubMed ID: 2140289
[TBL] [Abstract][Full Text] [Related]
10. Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
Cao S; Frank C; Rustum YM
J Natl Cancer Inst; 1996 Apr; 88(7):430-6. PubMed ID: 8618234
[TBL] [Abstract][Full Text] [Related]
11. [Biochemical modulation of 5-fluorouracil by high-dose leucovorin].
Aiba K
Gan To Kagaku Ryoho; 1988 Mar; 15(3):392-408. PubMed ID: 3279911
[TBL] [Abstract][Full Text] [Related]
12. Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin.
Romanini A; Lin JT; Niedzwiecki D; Bunni M; Priest DG; Bertino JR
Cancer Res; 1991 Feb; 51(3):789-93. PubMed ID: 1988119
[TBL] [Abstract][Full Text] [Related]
13. Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase.
van der Wilt CL; Pinedo HM; Smid K; Cloos J; Noordhuis P; Peters GJ
Semin Oncol; 1992 Apr; 19(2 Suppl 3):16-25. PubMed ID: 1532671
[TBL] [Abstract][Full Text] [Related]
14. [Comparison between leucovorin and cisplatin as a modulator of 5-fluorouracil].
Iba T; Yagi Y; Kidokoro A; Fukunaga T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):479-83. PubMed ID: 8452385
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of acquired resistance to modulation of 5-fluorouracil by leucovorin in HCT-8 human ileocecal carcinoma cells.
Lu K; McGuire JJ; Slocum HK; Rustum YM
Biochem Pharmacol; 1997 Mar; 53(5):689-96. PubMed ID: 9113088
[TBL] [Abstract][Full Text] [Related]
16. Leucovorin modulation of fluorouracil.
Grogan L; Sotos GA; Allegra CJ
Oncology (Williston Park); 1993 Aug; 7(8):63-72; discussion 75-6. PubMed ID: 8398636
[TBL] [Abstract][Full Text] [Related]
17. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin.
Rustum YM; Cao S; Zhang Z
Cancer J Sci Am; 1998; 4(1):12-8. PubMed ID: 9467039
[TBL] [Abstract][Full Text] [Related]
18. In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
Sugimoto Y; Ohe Y; Nishio K; Ohmori T; Fujiwara Y; Saijo N
Cancer Chemother Pharmacol; 1992; 30(6):417-22. PubMed ID: 1327567
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and in vitro studies of l-leucovorin. Comparison with the d and d,l-leucovorin.
Zittoun J
Ann Oncol; 1993; 4 Suppl 2():1-5. PubMed ID: 8353099
[TBL] [Abstract][Full Text] [Related]
20. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells.
Houghton JA; Morton CL; Adkins DA; Rahman A
Cancer Res; 1993 Sep; 53(18):4243-50. PubMed ID: 8364921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
